| Literature DB >> 28664083 |
Harshal Pawar1, Chhaya Varkhade1, Pravin Jadhav1, Kavita Mehra1.
Abstract
BACKGROUND: Orodispersible tablets or fast dissolving tablets dissolve or disintegrate immediately on the patients' tongue or buccal mucosa. This drug delivery system is suitable for drugs undergoing high first pass metabolism. It improves bioavailability, reduces dosing frequency, and thereby minimizes the side effects and also makes the dosage form more cost-effective. In this study, polysaccharide isolated from the seeds of Cassia tora was investigated as a superdisintegrant in the orodispersible tablets. The model drug chosen was valsartan, an antihypertensive drug.Entities:
Keywords: Cassia tora; direct compression; orodispersible tablets; patient compliance; sodium starch glycolate
Year: 2014 PMID: 28664083 PMCID: PMC5481693 DOI: 10.1016/j.imr.2014.03.002
Source DB: PubMed Journal: Integr Med Res ISSN: 2213-4220
Composition of orodispersible tablet
| Components mg/tablet | Formulation code | |||||||
|---|---|---|---|---|---|---|---|---|
| F1 | F2 | F3 | F4 | F5 | F6 | F7 | F8 | |
| Drug | 40 | 40 | 40 | 40 | 40 | 40 | 40 | 40 |
| Microcrystalline cellulose PH102 | 151.2 | 148.2 | 143.2 | 138.2 | 151.2 | 148.2 | 143.2 | 138.2 |
| 2 | 5 | 10 | 15 | – | – | – | – | |
| Sodium starch glycolate | – | – | – | – | 2 | 5 | 10 | 15 |
| Aspartame | 2.8 | 2.8 | 2.8 | 2.8 | 2.8 | 2.8 | 2.8 | 2.8 |
| Vanilla | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Talc | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Magnesium stearate | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Total weight | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 |
Physicochemical parameters of polysaccharide
| Parameters | Results |
|---|---|
| State | Solid |
| Color | Light brown |
| PH | 7.2–7.5 |
| Solubility | Soluble in hot water forming colloidal solution insoluble in organic solvent |
| Swelling factor | 11.5 mL |
| Practical yield | 18.56% w/w |
| Total ash | 1.47 |
| Moisture content | 1.2% |
| Total polysaccharide content | 72.12% w/w |
| Angle of repose | 29.24° |
| Bulk density | 0.64 g/cm3 |
| Tapped density | 0.53 g/cm3 |
| Carr's index | 17.16 |
| Hausner's ratio | 1.20 |
Fig. 1Fourier transform infrared spectrum of (A) pure drug, (B) pure drug + polysaccharide, and (C) optimized formulation F4.
Precompression parameters of powder blend
| Formulation code | Parameters | ||||
|---|---|---|---|---|---|
| Angle of repose ( | Bulk density (g/cm | Tapped density (g/cm | Carr's index (%) | Hausner's ratio | |
| F1 | 30.15 ± 1.21 | 0.50 ± 0.005 | 0.646 ± 0.009 | 22.67 ± 1.40 | 1.28 ± 0.025 |
| F2 | 29.20 ± 0.42 | 0.508 ± 0.002 | 0.637 ± 0.0098 | 20.37 ± 1.61 | 1.24 ± 0.031 |
| F3 | 28.78 ± 1.29 | 0.493 ± 0.03 | 0.654 ± 0.012 | 24.7 ± 1.66 | 1.32 ± 0.030 |
| F4 | 28.03 ± 1.20 | 0.491 ± 0.015 | 0.651 ± 0.009 | 24.54 ± 0.78 | 1.32 ± 0.015 |
| F5 | 27.65 ± 1.27 | 0.522 ± 0.003 | 0.649 ± 0.008 | 19.55 ± 1.40 | 1.23 ± 0.025 |
| F6 | 26.28 ± 0.91 | 0.515 ± 0.005 | 0.635 ± 0.005 | 18.89 ± 0.39 | 1.22 ± 0.005 |
| F7 | 30.84 ± 0.81 | 0.547 ± 0.003 | 0.627 ± 0.004 | 13.12 ± 0.005 | 1.14 ± 0.010 |
| F8 | 29.20 ± 1.78 | 0.539 ± 0.003 | 0.629 ± 0.004 | 14.39 ± 0.54 | 1.16 ± 0.005 |
Results are presented as mean ± SD, n = 5.
Postcompression parameters of orodispersible tablets of valsartan
| Formulation code | Parameters | |||
|---|---|---|---|---|
| Thickness | Hardness | Friability | Weight variation b | |
| F1 | 2.43 ± 0.11 | 4.56 ± 0.208 | 0.68 ± 0.01 | 200.2 ± 0.63 |
| F2 | 2.33 ± 0.15 | 4.40 ± 0.173 | 0.71 ± 0.01 | 200.2 ± 0.61 |
| F3 | 2.46 ± 0.05 | 4.43 ± 0.11 | 0.77 ± 0.01 | 199.7 ± 1.05 |
| F4 | 2.40 ± 0.12 | 4.2 ± 0.251 | 0.79 ± 0.01 | 200.5 ± 1.35 |
| F5 | 2.2 ± 0.11 | 4.33 ± 0.15 | 0.49 ± 0.015 | 200.2 ± 0.63 |
| F6 | 2.23 ± 0.20 | 4.53 ± 0.05 | 0.57 ± 0.017 | 200.2 ± 0.61 |
| F7 | 2.23 ± 0.057 | 4.46 ± 0.152 | 0.58 ± 0.069 | 199.7 ± 1.05 |
| F8 | 2.26 ± 0.014 | 4.3 ± 0.057 | 0.70 ± 0.015 | 200.5 ± 1.35 |
All values are presented as mean ± S D, n = 5 a/20 b.
Postcompression parameters of orodispersible tablets of valsartan
| Formulation code | Parameters | |||
|---|---|---|---|---|
| Wetting time | Water absorption ratio a | Drug content b | ||
| F1 | 60.27 ± 0.62 | 46.73 ± 0.39 | 110.88 ± 0.24 | 100.00 ± 002 |
| F2 | 57.29 ± 0.62 | 42.39 ± 0.35 | 119.04 ± 0.33 | 99.86 ± 0.1 |
| F3 | 47.68 ± 0.53 | 37.05 ± 0.56 | 126.80 ± 1.02 | 99.81 ± 0.18 |
| F4 | 32.34 ± 0.78 | 26.2 ± 0.25 | 133.55 ± 0.28 | 98.36 ± 0.43 |
| F5 | 70.56 ± 1.82 | 54.17 ± 0.48 | 99.67 ± 0.49 | 98.54 ± 0.85 |
| F6 | 61.32 ± 0.58 | 50.46 ± 0.76 | 99.24 ± 0.24 | 99.5 ± 0.77 |
| F7 | 55.16 ± 1.44 | 47.90 ± 0.44 | 104.66 ± 0.70 | 99.84 ± 0.33 |
| F8 | 46.96 ± 0.70 | 39.18 ± 0.43 | 109.52 ± 0.99 | 100.04 ± 0.20 |
All values are presented as mean ± SD, n = 6 a/10 b.
Fig. 2In vitro drug release profile of formulations (F1–F4 and marketed formulation).
Fig. 3In vitro drug release profile of formulations (F5–F8).
Stability study data for F4 batch
| Parameters | 1 mo | 2 mo | 3 mo |
|---|---|---|---|
| Hardness (kg/cm2) | 4.08 ± 0.09 | 4.22 ± 0.1 | 4.1 ± 0.12 |
| % Friability | 0.76 ± 0.09 | 0.79 ± 0.03 | 0.77 ± 0.05 |
| Drug content (%) | 99.53 ± 0.45 | 100.3 ± 0.1 | 99.95 ± 0.19 |
| Disintegration time(s) | 31.84 ± 0.6 | 30.12 ± 0.9 | 32.28 ± 0.1 |